Posted by Michael Wonder on 30 Jan 2017
Celgene receives positive CHMP opinion to expand Revlimid (lenalidomide) indication as monotherapy for the maintenance treatment of patients with newly diagnosed multiple myeloma after autologous stem cell transplantation
27 January 2017 - The new indication expands the availability of Revlimid across the disease continuum of multiple myeloma.
Celgene today announced that the EMA CHMP has adopted a positive opinion for the use of Revlimid as monotherapy for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation.
Once approved by the European Commission, Revlimid will be the first and only licensed maintenance treatment available to these patients.
